scholarly journals Impact of Immune Checkpoint Inhibitor on the Survival in Elderly Patients with Non-Small Cell Lung Cancer

2020 ◽  
pp. 1-5
Author(s):  
Minehiko Inomata ◽  
Minehiko Inomata ◽  
Kenji Azechi ◽  
Naoki Takata ◽  
Kana Hayashi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Elderly Patients ◽  
Small Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Small Cell ◽  
Small Cell Lung ◽  
History Of

Purpose: We analysed the relationship between a history of immune checkpoint inhibitor (ICI) and overall survival in elderly patients with non-small cell lung cancer (NSCLC). Methods: We conducted a retrospective analysis of the data of patients with NSCLC aged ≥70-year-old who had received systemic anticancer therapy between 2015 and 2019. Results: The analysis included the data of a total of 63 patients. Multivariate analysis revealed a significant association between a history of treatment with ICI and the overall survival. A significant interaction was also observed between a history of treatment with an ICI and the tumor histology. Conclusion: A significant association between history of ICI therapy and the overall survival was detected in elderly NSCLC patients aged ≥70-year-old in a clinical practice setting. Our results also suggested that the impact of ICI therapy on the survival differed depending on the tumor histology.

scholarly journals Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case–control study

2021 ◽  
Author(s):  
Takenori Ichimura ◽  
Miwa Hinata ◽  
Daisuke Ichikura ◽  
Shinya Suzuki
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Interstitial Pneumonia ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Small Cell ◽  
Small Cell Lung ◽  
History Of

Abstract Purpose The immune checkpoint inhibitor nivolumab is commonly used for non-small-cell lung cancer treatment. Immune checkpoint inhibitors cause immune-related adverse events, including interstitial pneumonia. However, there are no studies on the risk factors for interstitial pneumonia exacerbation after immune checkpoint inhibitor administration in patients with a history of different types of interstitial pneumonia. Therefore, we aimed to investigate the risk factors for interstitial pneumonia exacerbation in patients with non-small-cell lung cancer and a history of interstitial pneumonia. We also aimed to explore differences in the risk of interstitial pneumonia exacerbation due to various types of interstitial pneumonia—idiopathic interstitial pneumonia, immune-related pneumonitis, and radiation pneumonitis. Methods Eleven patients with a history of interstitial pneumonia exacerbation following the administration of immune checkpoint inhibitor were included in the study. We performed 1:2 matching based on age and sex. Twenty-two patients whose interstitial pneumonia did not worsen after immune checkpoint inhibitor administration belonged to the control group. We calculated odds ratios for each factor in the patients and control subjects. Results The odds ratio of idiopathic interstitial pneumonia in the case group was 0.15 (95% confidence interval: 0.03–0.89) (p = 0.03). There were no significant differences in other factors, such as smoking history, pulmonary emphysema, and chronic obstructive pulmonary disease. Conclusion The administration of immune checkpoint inhibitors in non-small-cell lung cancer patients with a history of idiopathic interstitial pneumonia might be a viable treatment option and have clinical benefits.

scholarly journals Impact of Immune Checkpoint Inhibitor Therapy on The Overall Survival in Elderly Patients With Non-Small Cell Lung Cancer

2020 ◽  
Author(s):  
Minehiko Inomata ◽  
Kenji Azechi ◽  
Naoki Takata ◽  
Kana Hayashi ◽  
Kotaro Tokui ◽  
...  
Keyword(s):  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Small Cell ◽  
Inhibitor Therapy ◽  
Small Cell Lung ◽  
History Of ◽  
Checkpoint Inhibitor Therapy

Abstract Purpose: We analyzed the relationship between a history of immune checkpoint inhibitor and overall survival in patients with non-small cell lung cancer (NSCLC) aged ≥ 70 years. Methods: We conducted a retrospective analysis of the data of patients with NSCLC aged ≥70 years old who had received systemic anticancer therapy at our institution between 2015 and 2019. Results: The analysis included the data of a total of 63 patients, including 36 patients who had received immune checkpoint inhibitor therapy and 27 patients who had not received treatment with an immune checkpoint inhibitor. Univariate analysis revealed a longer overall survival in patients who had received treatment with an immune checkpoint inhibitor as compared to those who had not received treatment with an immune checkpoint inhibitor (median: 17.2 vs. 9.8 months; p = 0.026, log-rank test). Multivariate analysis revealed a significant association between a history of treatment with immune checkpoint inhibitors and the overall survival (hazard ratio, 95% confidence interval: 0.42, 0.20-0.86; p = 0.019, Cox proportional hazards model). A significant interaction was also observed between a history of treatment with an immune checkpoint inhibitor and the tumor histology (p = 0.006), the association between the overall survival and a history of immune checkpoint inhibitor therapy being stronger in the non-small cell lung cancer patients with squamous cell carcinoma than in those with adenocarcinoma. Conclusion: A significant association between history of immune checkpoint inhibitor therapy and the overall survival was detected in elderly NSCLC patients aged ≥70 years old in a clinical practice setting. Our results also suggested that the impact of immune checkpoint inhibitor therapy on the survival differed depending on the tumor histology.

Sign in / Sign up

Export Citation Format

Share Document